Complete response of brain metastases to irinotecan-based chemotherapy

Rachel Chou; Allan Chen; Derick H Lau

doi:10.1016/j.jocn.2004.08.007

Complete response of brain metastases to irinotecan-based chemotherapy

Rachel Chou, Allan Chen, Derick H Lau

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Brain metastases occur in 15-20% of patients with cancer and are generally associated with an overall poor prognosis. Currently, radiotherapy and surgery are the mainstay of palliative therapy for patients with brain metastases, while the role of systemic chemotherapy remains uncertain. In this article, we report complete responses to irinotecan-based chemotherapy in three patients with brain metastases from parotid adenocarcinoma, esophageal adenocarcinoma and small cell lung cancer. Irinotecan-based chemotherapy may hold promise in treating patients with brain metastases. Further studies are warranted to confirm our observations.

Original language	English (US)
Pages (from-to)	242-245
Number of pages	4
Journal	Journal of Clinical Neuroscience
Volume	12
Issue number	3
DOIs	https://doi.org/10.1016/j.jocn.2004.08.007
State	Published - Apr 2005

Keywords

Brain metastases
Irinotecan
Whole brain radiation

ASJC Scopus subject areas

Clinical Neurology
Psychiatry and Mental health
Neurology

Access to Document

10.1016/j.jocn.2004.08.007

Fingerprint Dive into the research topics of 'Complete response of brain metastases to irinotecan-based chemotherapy'. Together they form a unique fingerprint.

Cite this

@article{6bd2dd8806d4482ca76ee36605a6b74c,

title = "Complete response of brain metastases to irinotecan-based chemotherapy",

abstract = "Brain metastases occur in 15-20% of patients with cancer and are generally associated with an overall poor prognosis. Currently, radiotherapy and surgery are the mainstay of palliative therapy for patients with brain metastases, while the role of systemic chemotherapy remains uncertain. In this article, we report complete responses to irinotecan-based chemotherapy in three patients with brain metastases from parotid adenocarcinoma, esophageal adenocarcinoma and small cell lung cancer. Irinotecan-based chemotherapy may hold promise in treating patients with brain metastases. Further studies are warranted to confirm our observations.",

keywords = "Brain metastases, Irinotecan, Whole brain radiation",

author = "Rachel Chou and Allan Chen and Lau, {Derick H}",

year = "2005",

month = apr,

doi = "10.1016/j.jocn.2004.08.007",

language = "English (US)",

volume = "12",

pages = "242--245",

journal = "Journal of Clinical Neuroscience",

issn = "0967-5868",

publisher = "Churchill Livingstone",

number = "3",

}

TY - JOUR

T1 - Complete response of brain metastases to irinotecan-based chemotherapy

AU - Chou, Rachel

AU - Chen, Allan

AU - Lau, Derick H

PY - 2005/4

Y1 - 2005/4

N2 - Brain metastases occur in 15-20% of patients with cancer and are generally associated with an overall poor prognosis. Currently, radiotherapy and surgery are the mainstay of palliative therapy for patients with brain metastases, while the role of systemic chemotherapy remains uncertain. In this article, we report complete responses to irinotecan-based chemotherapy in three patients with brain metastases from parotid adenocarcinoma, esophageal adenocarcinoma and small cell lung cancer. Irinotecan-based chemotherapy may hold promise in treating patients with brain metastases. Further studies are warranted to confirm our observations.

AB - Brain metastases occur in 15-20% of patients with cancer and are generally associated with an overall poor prognosis. Currently, radiotherapy and surgery are the mainstay of palliative therapy for patients with brain metastases, while the role of systemic chemotherapy remains uncertain. In this article, we report complete responses to irinotecan-based chemotherapy in three patients with brain metastases from parotid adenocarcinoma, esophageal adenocarcinoma and small cell lung cancer. Irinotecan-based chemotherapy may hold promise in treating patients with brain metastases. Further studies are warranted to confirm our observations.

KW - Brain metastases

KW - Irinotecan

KW - Whole brain radiation

UR - http://www.scopus.com/inward/record.url?scp=17844383213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844383213&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2004.08.007

DO - 10.1016/j.jocn.2004.08.007

M3 - Article

C2 - 15851073

AN - SCOPUS:17844383213

VL - 12

SP - 242

EP - 245

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

IS - 3

ER -